Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults

ClinicalTrials.gov ID: NCT02610868

Public ClinicalTrials.gov record NCT02610868. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 21, 2026, 6:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Long-Term, Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adult Subjects

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Multicenter, open-label, outpatient study of the safety and effectiveness of repeated doses of MYOBLOC over a 1-year duration in adult subjects with troublesome sialorrhea.

Study identification

NCT ID: NCT02610868
Recruitment status: Completed
Study type: Interventional
Phase: Phase 3
Lead sponsor: Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC; Industry
Enrollment: 187 participants

Conditions and interventions

Conditions

Sialorrhea

Interventions

MYOBLOC Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 85 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 2015 (Type not available)
Primary completion: Jun 2017 (Actual)
Completion: Jun 2017 (Actual)
Last update posted: Apr 21, 2026

2015 – 2017

United States locations

U.S. sites: 26
U.S. states: 17
U.S. cities: 25

Facility	City	State	ZIP	Site status
Not listed	Phoenix	Arizona	85013	—
Not listed	Scottsdale	Arizona	85258	—
Not listed	Scottsdale	Arizona	85259	—
Not listed	Loma Linda	California	92354	—
Not listed	Los Angeles	California	90033	—
Not listed	Aurora	Colorado	80045	—
Not listed	Atlantis	Florida	33462	—
Not listed	Boca Raton	Florida	33486	—
Not listed	Orlando	Florida	32806	—
Not listed	Port Charlotte	Florida	33980	—
Not listed	Atlanta	Georgia	30329	—
Not listed	Kansas City	Kansas	66160	—
Not listed	Overland Park	Kansas	66211	—
Not listed	Elkridge	Maryland	21075	—
Not listed	Farmington Hills	Michigan	48334	—
Not listed	St Louis	Missouri	63110	—
Not listed	Las Vegas	Nevada	89145	—
Not listed	Edison	New Jersey	08818	—
Not listed	Centerville	Ohio	45459	—
Not listed	Tulsa	Oklahoma	74136	—
Not listed	Greenville	South Carolina	29615	—
Not listed	Cordova	Tennessee	38018	—
Not listed	San Antonio	Texas	78229	—
Not listed	Kirkland	Washington	98034	—
Not listed	Spokane	Washington	99202	—
Not listed	Tacoma	Washington	98409	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02610868, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 21, 2026 · Synced Oct 21, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02610868 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →